Eckert & Ziegler to Run Tumor Radiation Business Through TCL Healthcare Equipment
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Joint Venture
Berlin, 18 September 2020. Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) plans to run its business with tumor radiation equipment together with TCL Healthcare Equipment (Shanghai) Co., Ltd. (TCL). The two companies today signed a binding letter of intent under which EZAG will transfer its division with the so-called afterloaders (HDR brachytherapy) to a separate company in which TCL will acquire 51% of the shares. Sales revenues with HDR brachytherapy products amounted to approximately EUR 11 million in fiscal year 2019. The transaction is expected to be completed by the end of 2020.
Information and Explanation of the Issuer to this News:
'TCL is the right partner for the business with tumor radiation equipment', said Dr. Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG. 'TCL shares both our strategy and our values and is therefore the best choice to drive the growth of the HDR business worldwide'. With TCL we already run a joint venture for the Chinese market since 2019. This cooperation is now being expanded to strengthen our worldwide commercialization of HDR devices. The production shall remain in Germany.
TCL Healthcare Equipment (Shanghai) Co., Ltd., headquartered in Shanghai, is an innovative supplier of diagnostic imaging equipment focusing to provide comprehensive healthcare products and solutions to the healthcare providers.
About Eckert & Ziegler.
18-Sep-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Eckert & Ziegler Strahlen- und Medizintechnik AG|
|Phone:||+49 30 941084-138|
|Fax:||+49 30 941084-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1133429|
|End of Announcement||DGAP News Service|